Key stats
About Virtus LifeSci Biotech Products ETF
Home page
Inception date
Dec 17, 2014
Structure
Open-Ended Fund
Distributes
Capital Gains
Max ST capital gains rate
39.60%
Max LT capital gains rate
20.00%
Tax on distributions
Qualified dividends
Primary advisor
Virtus ETF Advisers LLC
Distributor
VP Distributors LLC
BBP offers a different approach to biotech investing by handpicking firms whose lead drugs are on its product stage or those firms that have attained FDA approval for their leading drug. Stocks must earn a majority of their revenue from the research and development and/or marketing and sale of novel drugs or other therapeutics used in the treatment of human diseases. The fund is offered by BioShares alongside launched a sister fund, BBC, which targets biotech firms in the clinical trial stage. The index is reconstituted on a semi-annual basis.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Stocks99.46%
Health Technology99.46%
Bonds, Cash & Other0.54%
Cash0.54%
Stock breakdown by region
North America87.88%
Europe9.92%
Asia2.19%
Latin America0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings
Symbol
Assets
Symbol
Assets
I
Intra-Cellular Therapies, Inc.ITCI
2.59%
O
BeiGene Ltd Sponsored ADRONC
2.35%
S
SAGE Therapeutics, Inc.SAGE
2.20%
S
Springworks Therapeutics, Inc.SWTX
2.18%
Z
Zai Lab Ltd. Sponsored ADRZLAB
2.18%
A
Axsome Therapeutics, Inc.AXSM
2.17%
G
Gilead Sciences, Inc.GILD
2.09%
H
Halozyme Therapeutics, Inc.HALO
2.07%
B
BridgeBio Pharma, Inc.BBIO
1.92%
A
Amgen Inc.AMGN
1.91%
Top 10 weight21.65%
63 total holdings